-
Mashup Score: 5
PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated an
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study - PubMed - 2 month(s) ago
We present a hypofractionated schedule of postoperative prostate radiotherapy that is both well tolerated in terms of both toxicity and quality of life measures. Initial PSA control is encouraging. Further evaluation with a longer follow-up and a larger cohort is warranted.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
We changed our postop practice during covid to 51/17 (based on #PHART4) but based on CCO funding now do 52.5/20 based on @PCaParker #RADICALS study. Who else is going further to UHF doses? Chia-Lin Tseng is leading our #PLUTO program (30/5 +- 25/5 ENI) https://t.co/SKYyGZiQ6E https://t.co/iQdHv9nQC8
-
-
Mashup Score: 11Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial - PubMed - 6 month(s) ago
PRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer—Quo Vadimus? - World Journal of Urology - 6 month(s) ago
Purpose Stereotactic body radiotherapy (SBRT) is an emerging treatment option for localized prostate cancer. There is increasing interest to reduce the number of fractions for prostate SBRT. Methods We provide a narrative review and summary of prospective trials of different fractionation schedules for prostate SBRT, focusing on efficacy, toxicities, and quality of life outcomes. Results There…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer-specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with RP.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
External beam radiotherapy (EBRT) is a curative treatment for Localized Prostate Cancer (LPCa). Large randomized controlled trials (RCTs) have shown moderately hypo fractionated regimens (2.5 – 3 Gy/fraction(f)) as non-inferior to 2Gy/f regimens. PACE-B aims to demonstrate non-inferiority of SBRT compared to conventionally or moderately hypo fractionated regimens for biochemical and/or clinical failure (BCF).
Source: www.redjournal.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities - PubMed - 7 month(s) ago
Despite increasing utilization, many men do not receive multidisciplinary care prior to radical prostatectomy. While geography and the urologist appear to be the greatest factors predicting multidisciplinary care receipt, these factors are closely intertwined.
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 7Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer - 8 month(s) ago
There is no evidence-based data to guide dose constraints in two-fraction prostate stereotactic ablative radiotherapy (SABR). Using individual patient…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0I left the U.S. for Paris 12 years ago—6 things French people do differently than Americans to live long, happy lives - 10 month(s) ago
After moving from New York to Paris in 2011, Ajiri Aki discovered a new, more joyful perspective on life. Here’s what the mother and lifestyle guru learned from French people about how to live a long, happy life.
Source: CNBCCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
4yPSARR is an encouraging early predictor of outcome in patients with intermediate-risk PCa treated with SBRT. Validation in prospective trials is warranted.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
Not surprisingly there are no differences in toxicity (measured by admin data, prospective data coming but also negative to date) no efficacy between: Protons and Photons Yet HUGE cost difference. So why are protons still offered? https://t.co/YOjWCFXEGd https://t.co/DJmVKepTbt